Fmr Llc ownership in 4XC1 / KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

DE ˙ DB ˙ US4834971032

23,01 € 0,00 (0,00%)

2026-06-04
AKTIENPREIS

Security	DE:4XC1 / KalVista Pharmaceuticals, Inc.
Institution	Fmr Llc
Latest Disclosed Ownership	50,970 shares
Ownership	0.15%

2024-02-09 - Fmr Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 50,970 shares of KalVista Pharmaceuticals, Inc. (DE:4XC1). This represents 0.147 percent ownership of the company. In their previous filing dated 2023-02-09 , Fmr Llc had reported owning 1,311,002 shares, indicating a decrease of -96.11 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2024-02-09	2024-02-09	13G/A	1,311,002	50,970	-96.11	0.15	-97.24
2023-02-09	2023-02-09	13G	1,011,500	1,311,002	29.61	5.33	28.59
2021-06-10	2021-06-10	13G/A	1,640,278	1,011,500	-38.33	4.14	-54.70
2021-02-08	2021-02-08	13G/A	1,790,791	1,640,278	-8.40	9.14	-8.89
2020-04-10	2020-04-10	13G/A	1,666,978	1,790,791	7.43	10.03	7.35
2020-02-07	2020-02-07	13G		1,666,978		9.35
2016-05-10	2016-05-10	13G/A	1,952,045	600	-99.97	0.00	-99.97
2016-04-11	2016-04-11	13G/A	3,365,147	1,952,045	-41.99	7.41	-42.01
2016-02-12	2016-02-12	13G/A	3,306,736	3,365,147	1.77	12.78	1.28
2015-05-11	2015-05-11	13G		3,306,736		12.62

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	187,848	76,041	68.01	3,781	109.47	0.0000
2026-02-17	2025-12-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	111,807	19,439	21.05	1,806	60.44	0.0001
2025-11-13	2025-09-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	92,368	-41,198	-30.84	1,125	-25.45	0.0001
2025-08-14	2025-06-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	133,566	50,670	61.12	1,510	57.85	0.0001
2025-05-12	2025-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	82,896	891	1.09	957	37.75	0.0001
2025-02-13	2024-12-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	82,005	15,582	23.46	695	-9.75	0.0000
2024-11-13	2024-09-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	66,423	12,397	22.95	769	20.91	0.0000
2024-08-13	2024-06-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	54,026	3,119	6.13	636	5.47	0.0000
2024-05-13	2024-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	50,907	-63	-0.12	604	-3.37	0.0000
2024-02-13	2023-12-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	50,970	-6,596	-11.46	624	12.64	0.0000
2023-11-13	2023-09-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	57,566	-13,299	-18.77	554	-13.03	0.0000
2023-08-11	2023-06-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	70,865	-30	-0.04	638	14.36	0.0001
2023-08-11	2023-03-31	13F/A-1	KALVISTA PHARMACEUTICALS	COM	483497103	70,895	-1,240,107	-94.59	557	-93.71	0.0001
2023-05-11	2023-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	70,895	-1,240,107		557		0.0001
2023-02-13	2022-12-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,311,002	152,617	13.17	8,862	-47.28	0.0009
2022-11-10	2022-09-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,158,385	25,943	2.29	16,808	50.84	0.0018
2022-08-12	2022-06-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,132,442	307,092	37.21	11,143	-8.41	0.0011
2022-05-13	2022-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	825,350	38,130	4.84	12,166	16.81	0.0010
2022-02-14	2021-12-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	787,220	-173,741	-18.08	10,415	-37.89	0.0008
2022-02-14	2021-09-30	13F/A-1	KALVISTA PHARMACEUTICALS	COM	483497103	960,961	-127,829	-11.74	16,769	-35.72	0.0013
2021-11-15	2021-09-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	960,961	-127,829		16,769		0.0013
2021-08-13	2021-06-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,088,790	-259,180	-19.23	26,087	-24.67	0.0020
2021-05-14	2021-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,347,970	-292,308	-17.82	34,630	11.18	0.0030
2021-02-08	2020-12-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,640,278	-101,335	-5.82	31,149	42.06	0.0028
2020-11-13	2020-09-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,741,613	-22,243	-1.26	21,926	2.74	0.0022
2020-08-24	2020-06-30	13F/A-1	KALVISTA PHARMACEUTICALS	COM	483497103	1,763,856	-26,935	-1.50	21,342	55.78	0.0023
2020-08-13	2020-06-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,763,856	-26,935		21,342		524.3105
2020-05-14	2020-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,790,791	123,813	7.43	13,700	-53.85	0.0019
2020-02-07	2019-12-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	1,666,978	742,033	80.22	29,689	176.72	0.0033
2019-11-13	2019-09-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	924,945	-51,535	-5.28	10,729	-50.40	0.0013
2019-08-13	2019-06-30	13F	KALVISTA PHARMACEUTICALS	COM	483497103	976,480	241,466	32.85	21,629	2.82	0.0025
2019-05-13	2019-03-31	13F	KALVISTA PHARMACEUTICALS	COM	483497103	735,014	735,014		21,036		0.0025

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.